Gravitas Feeding Tube System Placement Validation in Neonates

Sponsor
Gravitas Medical, Inc. (Industry)
Overall Status
Not yet recruiting
CT.gov ID
NCT05914064
Collaborator
(none)
110
2
5

Study Details

Study Description

Brief Summary

The purpose of this study is to validate the Gravitas Feeding Tube System Placement Algorithm for NICU patients and to evaluate the safety and effectiveness of the Gravitas Feeding Tube in the neonate population for the administration of nutrition, fluids and medications.

Condition or Disease Intervention/Treatment Phase
  • Device: Gravitas FT and Gravitas FT Monitor guidance
  • Device: Gravitas FT System without placement guidance
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
110 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Gravitas Feeding Tube System Placement Validation in Neonates
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Gravitas FT System

Device: Gravitas FT and Gravitas FT Monitor guidance
FT placed with guidance from the Gravitas FT system

Active Comparator: Control

Device: Gravitas FT System without placement guidance
SOC placement

Outcome Measures

Primary Outcome Measures

  1. Incidence of device and procedure-related adverse events that occur while the feeding tube is within a subject. The number and type of adverse events will be collected. [1 year]

Eligibility Criteria

Criteria

Ages Eligible for Study:
0 Weeks to 18 Weeks
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Infants in the Newborn Intensive Care Unit or on the general medical floor requiring a 5-8 Fr NG tube. The desired size of the feeding tube should be determined clinically, and the Gravitas 5-8 Fr Feeding Tube should only be placed if that size is appropriate.

  • Age at enrollment: 0 to 18 weeks post-partum. Can be up to 12 weeks preterm (gestational age ≥ 28 weeks).

  • Suitable to start enteral (gastric but not post-pyloric) feeding

  • Anticipated to receive enteral feeding (either bolus or continuous feeds) for more than 6 hours. If enteral nutrition has already been initiated, indicated for replacement of an orogastric/nasogastric feeding tube.

  • Ability to have a legally authorized representative provide informed consent Both neonates on a ventilator (non-invasive or invasive ventilation) or not requiring a ventilator are eligible for this study.

Exclusion Criteria:
  • Known major upper airway malformation (e.g. tracheoesophageal fistula)

  • Known major GI malformation (e.g. malrotation)

  • NPO status - neonate expected to remain NPO/NPG for the following 72 hours

  • Has a medical condition that drastically affects gastric acid-secretion (e.g. Zollinger-Ellison Syndrome, congenital achlorhydria, gastrointestinal perforation/leak/obstruction);

  • Has had removal of part of the stomach

  • Critically ill, facing imminent death

  • Neonate on ECMO

  • Deemed unsuitable for enrollment in study by the site principal investigator based on the patients' medical history

  • Infant needs an MRI in the immediate future (e.g. 6-12h)

  • Infant needs post-pyloric feeds (distal to stomach)

  • Infant has a basilar skull fracture

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Gravitas Medical, Inc.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Gravitas Medical, Inc.
ClinicalTrials.gov Identifier:
NCT05914064
Other Study ID Numbers:
  • CRD-04-1645-01
First Posted:
Jun 22, 2023
Last Update Posted:
Jun 22, 2023
Last Verified:
Jun 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No

Study Results

No Results Posted as of Jun 22, 2023